Evidence map›Paper›PMID 40673694›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2025

Understanding the Impact of Antiretroviral Therapy and Other Factors on HPV Clearance in Cisgender Women With HIV/HPV Coinfections in the DC Cohort.

Halah G Jadallah, Lauren F O'Connor, Morgan Byrne, Anuja Baskaran, Michael Horberg, Amanda D Castel, Anne K Monroe, DC Cohort Executive Committee

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Halah G JadallahMilken Institute School of Public Health, The George Washington University, Washington, DC; and.
Lauren F O'ConnorMilken Institute School of Public Health, The George Washington University, Washington, DC; and.
Morgan ByrneMilken Institute School of Public Health, The George Washington University, Washington, DC; and.
Anuja BaskaranMilken Institute School of Public Health, The George Washington University, Washington, DC; and.
Michael HorbergKaiser Permanente Mid-Atlantic Permanente Medical Group, Washington, DC.
Amanda D CastelMilken Institute School of Public Health, The George Washington University, Washington, DC; and.
Anne K MonroeMilken Institute School of Public Health, The George Washington University, Washington, DC; and.
DC Cohort Executive Committee

Funding

The DC Cohort: A Longitudinal Population-Based Cohort Study of People Living with HIV in Washington, DCR24AI152598 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Amanda Derryck Castel, Marinella Temprosa · 2020 to 2026
$37.9M
National Institute of Allergy and Infectious Diseases 1R24AI152598-01NIAID NIH HHS R24 AI152598
6 · The paper itself

Abstract

backgroundWomen with HIV are at an elevated risk for HPV. Antiretroviral therapy (ART) effectively treats HIV; however, there is no noninvasive pharmacologic treatment for HPV. Previous studies have shown varied effects of ART class on HPV clearance, with some demonstrating an association. Our objective was to evaluate the association between ART class and HPV clearance among women with HIV/HPV coinfections.

methodsWe analyzed electronic health records from participants with HPV in the DC Cohort Longitudinal HIV Study from time at HPV detection to January 1, 2024. We investigated time to HPV clearance based on time-updated ART status using Cox proportional hazards and Kaplan-Meier models, focusing on protease inhibitors (PIs) and integrase strand transfer inhibitors.

resultsAmong 362 women with HIV/HPV coinfections, 94.8% were non-Hispanic Black, 81.2% had public insurance, and 45.6% were smokers. Overall, 74.0% cleared their HPV infection. A higher proportion of participants who cleared HPV were on PIs at baseline compared with those who did not ( P = 0.03). Those who did not achieve clearance had lower nadir CD4 counts ( P = 0.04) and did not achieve viral suppression ( P = 0.0005). In the survival analysis, women on PI-based regimens had shorter time to HPV clearance than those on integrase strand transfer inhibitors (HR = 2.12, 95% CI: 1.39 to 3.24).

conclusionsThis study suggests that PIs may be associated with a higher likelihood of HPV clearance among women with HIV. Our results provide evidence on the influence of clinical and sociodemographic factors, including ART, that may affect HPV clearance among women with HIV.Key words: HIV/HPV co-infection, antiretrovial therapy, HPV clearance.

Indexed as

Anti-Retroviral AgentsHIV InfectionsPapillomavirus InfectionsAdultBlack or African AmericanCoinfectionDistrict of ColumbiaElectronic Health RecordsFemaleHIV Protease InhibitorsHumansLongitudinal StudiesMiddle AgedProspective StudiesTime FactorsAnti-Retroviral AgentsHIV Protease Inhibitors

Identifiers

PMID40673694
PMCPMC12363480

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.